Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyQvia Dosing Frequency in Primary Immunodeficiency
NCT02881437Phase 4Completed
- Sponsor
- CHU de Lille
- Start
- Nov 2016
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of Human normal immunoglobulin G in primary immunodeficiency (PI), sponsored by CHU de Lille. Started Nov 2016; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT02881437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881437.